Study of KCNJ11 rs5219 Gene Polymorphism on the Efficacy of Metformin Combined with Gliclazide in Newly Diagnosed Diabetes Mellitus Type 2 Patients
10.13748/j.cnki.issn1007-7693.20230241
- VernacularTitle:KCNJ11 rs5219基因多态性对新发2型糖尿病患者二甲双胍及格列齐特联用疗效的研究
- Author:
Lie XIONG
1
,
2
;
Fang YAO
3
,
4
;
Limin JIN
4
;
Fan NING
4
,
4
;
Hanqiang SHI
1
,
4
;
Shuqin DU
5
;
Yanbo SHI
1
,
4
Author Information
1. Zhejiang Chinese Medical University Affiliated Jiaxing Traditional Chinese Medicine Hospital, Central Laboratory, Jiaxing 314000, China
2. Jiaxing Key Laboratory of Diabetic Angiopathy Research, Jiaxing 314000, China
3. Zhejiang Chinese Medical University Affiliated Jiaxing Traditional Chinese Medicine Hospital, Department of Endocrine, Jiaxing 314000, China
4. Jiaxing Key Laboratory of Diabetic Angiopathy Research, Jiaxing 314000, China
5. College of Pharmacy, Zhejiang University of Technology, Hangzhou 310000, China 摘要
- Publication Type:Clinical Trial
- Keywords:
diabetes mellitus type 2 , MassARRAY , single nucleotide polymorphism , KCNJ11 , rs5219
- From:
Chinese Journal of Modern Applied Pharmacy
2023;40(24):3431-3438
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:OBJECTIVE To explore the effect of the polymorphisms of ATM(rs11212617), KCNJ11(rs5219), CYP2C9(rs1799853, rs1057910), TCF7L2(rs12255372, rs290487) and IRS1(rs1801278) on efficacy of metformin and gliclazide combined treatment for diabetes mellitus type 2. METHODS Eighty-one patients with newly diagnosed diabetes mellitus type 2 in Standardized Metabolic Disease Management Center of the Endocrinology Department of of Zhejiang Chinese Medical University Affiliated Jiaxing TCM Hospital were enrolled in this study, and they were treated with metformin hydrochloride tablets and gliclazide modified release tablets. MassARRAY was used to type the above single nucleotide polymorphism(SNP), and followed up for 3 months. Fasting plasma glucose(FPG), glycosylated hemoglobin type Alc(HbA1c) and fasting insulin(FINS) were compared before and after treatment. RESULTS The gene frequencies of all SNPs were compliant to Hardy-Weinberg equilibrium, the samples were well represented. The rs1799853, rs1057910, rs12255372 and rs1801278 had low mutation frequencies with poor clinical significance. The benefits of FPG compliance rate, increase of FINS, decrease of HbAlc after treatment were stronger in patients with homozygous rs5219 C allele than those with T-allele carriers (P<0.05). However, there were no significant differences in treatment effects among the genotypes of rs11212617 and rs290487. CONCLUSION The rs5219 polymorphism of KCNJ11 gene is associated with the efficacy of metformin hydrochloride tablets and gliclazide modified release tablets in treating diabetes mellitus type 2, with a more significant effect observed in individuals homozygous for the C allele. This finding can serve as a reference for personalized medication in clinical treatment of diabetes mellitus type 2.
